We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

89 hedge funds and large institutions have $426M invested in Endocyte, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

395% more capital invested

Capital invested by funds: $86.1M → $426M (+$340M)

120% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 15

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

54% more call options, than puts

Call options by funds: $4.91M | Put options by funds: $3.19M

25% more funds holding

Funds holding: 71 → 89 (+18)

Holders
89
Holders Change
+18
Holders Change %
+25.35%
% of All Funds
2.04%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
33
Increased
27
Reduced
14
Closed
15
Calls
$4.91M
Puts
$3.19M
Net Calls
+$1.73M
Net Calls Change
+$2.78M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$31.4M
2
VMI
VHCP Management II
New York
+$23.7M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$17.2M
4
DM
Deerfield Management
New York
+$14.5M
5
GTC
Ghost Tree Capital
New York
+$12.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.37M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.55M
3
Millennium Management
Millennium Management
New York
-$745K
4
BCM
Bridgeway Capital Management
Texas
-$662K
5
Renaissance Technologies
Renaissance Technologies
New York
-$547K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$1.82M +$1.1M +200,000 New
Morgan Stanley
27
Morgan Stanley
New York
$1.8M +$172K +31,256 +19%
Renaissance Technologies
28
Renaissance Technologies
New York
$1.77M -$547K -99,080 -34%
Millennium Management
29
Millennium Management
New York
$1.72M -$745K -135,095 -42%
BCM
30
Bridgeway Capital Management
Texas
$1.59M -$662K -120,000 -41%
BCM
31
BlueCrest Capital Management
Jersey
$1.55M +$944K +171,019 New
OAM
32
Oxford Asset Management
United Kingdom
$1.49M +$409K +74,199 +83%
MIM
33
Monashee Investment Management
Massachusetts
$1.32M +$801K +145,121 New
TEE
34
Tibra Equities Europe
United Kingdom
$1.27M +$772K +139,972 New
TD Asset Management
35
TD Asset Management
Ontario, Canada
$1.24M +$750K +135,931 New
Northern Trust
36
Northern Trust
Illinois
$1.18M +$269K +48,770 +60%
ACM
37
Asymmetry Capital Management
California
$831K +$54.9K +9,951 +12%
Baird Financial Group
38
Baird Financial Group
Wisconsin
$818K +$497K +90,019 New
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$773K – – –
ECM
40
Element Capital Management
New York
$699K +$424K +76,936 New
Barclays
41
Barclays
United Kingdom
$614K -$196K -35,466 -34%
Axa
42
Axa
France
$518K +$185K +33,535 +143%
Bank of America
43
Bank of America
North Carolina
$482K -$80.1K -14,511 -21%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$478K +$6.62K +1,199 +2%
PCM
45
Prelude Capital Management
New York
$478K +$54.9K +9,948 +23%
MCM
46
Moore Capital Management
New York
$455K +$276K +50,000 New
State Street
47
State Street
Massachusetts
$451K +$179K +32,500 +190%
DZ Bank
48
DZ Bank
Germany
$438K +$266K +48,200 New
CCM
49
Cribstone Capital Management
Maine
$430K – – –
VF
50
Virtu Financial
New York
$398K +$149K +26,936 +160%
1
2
3 4 5

ECYT Hedge Fund Activity: Q1 2018 in Review

89 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2018, worth a combined $426M — up 395% from $86.1M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ECYT positions and 15 closed out — a net gain of 18 holders — while 27 added to existing stakes and 14 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $31.4M. The largest seller was Fidelity Investments, cutting an estimated $9.37M.

  • 89 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2018, up from 71 in Q4 2017.
  • Funds reported $426M of Endocyte, Inc. Common Stock stock for Q1 2018, up 395% quarter-over-quarter.
  • 33 funds opened new Endocyte, Inc. Common Stock positions in Q1 2018 and 15 closed out, a net change of +18 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q1 2018 was Avoro Capital Advisors, an estimated $31.4M added.
  • The largest Endocyte, Inc. Common Stock seller in Q1 2018 was Fidelity Investments, an estimated $9.37M sold.

Based on aggregated 13F filings for Q1 2018.